High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in Sao Paulo, Brazil

Imagem de Miniatura
Arquivos
art_VIDAL_High_rate_of_virologic_suppression_with_darunavir_ritonavir_2013.PDF (288.7 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2013
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CONTEXTO
Autores
MATOS, Maria Laura
BARTMANN, Daniel
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.17, n.1, p.41-47, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil. Methods: Prospective cohort study carried out in a tertiary center in Sao Paulo, Brazil. Three-class antiretroviral-experienced patients with confirmed virologic failure began darunavir/ritonavir plus optimized background therapy (nucleoside/tide reverse transcriptase inhibitors +/- raltegravir +/- enfuvirtide +/- maraviroc) after performing a genotypic resistance assay. Clinical evaluation and laboratory tests were collected at baseline and at weeks 12, 24, and 48. Multivariate analysis was performed to identify predictors of virologic response at 48 weeks. Results: Ninety-two patients were included. The median of darunavir resistant mutation was 1 (range 0-6). The median genotypic sensitivity score in the optimized background therapy was 2 (interquartile range 1-2). At week 48, 83% (95% CI: 75-90%) had an HIV RNA level <50 copies/mL and the median CD4 cell count was 301 (interquartile range 224-445) cells/mm(3). Baseline HIV RNA >100 000 copies/mL was inversely associated with virologic success at week 48 (HR: 0.22, 95% CI: 0.06-0.85, p=0.028). Conclusions: Darunavir/ritonavir plus optimized background therapy was a highly effective salvage regimen under clinical routine conditions in a referral center in Brazil, which is similar to the reported in high-income countries.
Palavras-chave
Highly active antiretroviral therapy, Darunavir, Acquired immunodeficiency syndrome, Developing countries
URI
https://observatorio.fm.usp.br/handle/OPI/1978
Referências
  1. BRUNDAGE MD, 1993, J NATL CANCER I, V85, P1138, DOI 10.1093/jnci/85.14.1138
  2. Burgos J, 2012, J ANTIMICROB CHEMOTH, V67, P1453, DOI 10.1093/jac/dks057
  3. Pujades-Rodriguez M, 2008, AIDS, V22, P1305, DOI 10.1097/QAD.0b013e3282fa75b9
  4. Capetti AF, 2009, JAIDS-J ACQ IMM DEF, V50, P233, DOI 10.1097/QAI.0b013e31818c7e8e
  5. Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S01406736(07)60497-8
  6. Delaugerre C, 2010, J CLIN VIROL, V47, P248, DOI 10.1016/j.jcv.2009.12.022
  7. Fatkenheuer G, 2008, NEW ENGL J MED, V359, P1442, DOI 10.1056/NEJMoa0803154
  8. Gallant JE, 2007, INFECT DIS CLIN N AM, V21, P85, DOI 10.1016/j.idc.2007.01.003
  9. Imaz A, 2011, J ANTIMICROB CHEMOTH, V66, P358, DOI 10.1093/jac/dkq432
  10. Imaz A, 2011, AIDS REV, V13, P180
  11. Imaz A, 2009, JAIDS-J ACQ IMM DEF, V52, P382, DOI 10.1097/QAI.0b013e3181b17f53
  12. Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e
  13. Mauskopf J, 2010, PHARMACOECONOMICS, V28, P83, DOI 10.2165/11587470-000000000-00000
  14. Moeremans K, 2010, PHARMACOECONOMICS, V28, P107, DOI 10.2165/11587480-000000000-00000
  15. Munerato P, 2010, AIDS RES HUM RETROV, V26, P265, DOI 10.1089/aid.2009.0288
  16. Panel on Antiretroviral Guidelines for Adults and Adolescents, 2012, PANEL ON ANTIRETROVI
  17. Picchio G, 2007, 14TH CONFERENCE ON R
  18. Pichenot M, 2012, HIV MED, V13, P148, DOI 10.1111/j.1468-1293.2011.00953.x
  19. Poveda E, 2007, J ANTIMICROB CHEMOTH, V60, P885, DOI 10.1093/jac/dkm276
  20. Renaud-Thery F, 2007, AIDS, V21, pS89, DOI 10.1097/01.aids.0000279711.54922.f0
  21. Ribera E, 2007, ENFERM INFEC MICR CL, V25, P131, DOI 10.1157/13098573
  22. Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
  23. Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
  24. Vidal JE, 2011, BRAZ J INFECT DIS, V15, P245
  25. Wilson LE, 2009, CLIN INFECT DIS, V48, P214, DOI 10.1086/595701
  26. World Health Organization UNAIDS UNICEF., 2008, PROGRESS REPORT
  27. Yazdanpanah Y, 2009, CLIN INFECT DIS, V49, P1441, DOI 10.1086/630210

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/Outros
Artigos e Materiais de Revistas Científicas - LIM/47
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - LIM/54
Carregar mais